Background {#Sec1}
==========

Renal cell carcinoma (RCC) is associated with high mortality, accounts for approximately 80--85% of all renal tumors, and is the most common type of adult kidney cancer with poor prognosis \[[@CR1]\]. Approximately 30% RCC patients already have metastatic lesions upon initial diagnosis \[[@CR2]\]. Renal cell carcinoma (RCC) is highly resistant to both chemotherapy and radiotherapy \[[@CR3]\]. Early diagnosis of patients with RCC would significantly improve their prognosis and quality of life \[[@CR4]--[@CR6]\]. The incidence of survival is very low, since most RCC patients have developed metastases beyond the kidney tissue when the RCC is diagnosed \[[@CR4], [@CR7], [@CR8]\]. Early diagnosis for the disease of RCC is very difficult, and the RCC etiology is complicated \[[@CR4], [@CR8]\]. Gene polymorphisms are reported to be associated with susceptibility of many diseases \[[@CR9]--[@CR13]\]. Current evidence also shows some gene polymorphisms to be associated with RCC risk \[[@CR14]--[@CR17]\].

The glutathione S-transferases (GSTs) is a family of isozymes including GSTM1, GSTT1, and GSTP1 classes, and can catalyze the glutathione to detoxify xenobiotics \[[@CR18], [@CR19]\]. GSTs conjugate glutathione (GSH), a scavenger peptide, with electrophilic compounds \[[@CR20], [@CR21]\], and are known to play a pivotal role in the detoxification of some potential carcinogens \[[@CR22], [@CR23]\]. It has also been suggested that certain *GST* gene polymorphisms, leading to altered detoxification activity, predispose individuals to certain cancers, such as prostate cancer, hepatocellular carcinoma, and colorectal cancer \[[@CR24]--[@CR26]\].

Previously, most epidemiologic investigations have detected a relationship between the *GSTM1/GSTT*-null phenotype, the *GSTP1* A/G gene polymorphism, and RCC risk. But, the current evidence is inadequate, for the reason that sparseness of data or inconsistencies among these reported investigations. This meta-analysis was conducted to assess whether the null genotype of *GSTM1/GSTT1* and the *GSTP1* A/G gene polymorphism are associated with RCC susceptibility by ethnicity, and whether there is an association between the null genotype of *GSTM1/GSTT1* and clinical TNM stages in patients with RCC by ethnicity, due to the fact that the genotype distributions of the different populations might differ from each other \[[@CR27], [@CR28]\]. We also evaluated the publication bias for the relationship between the *GSTM1*-null genotype, *GSTT1*-null genotype, dual *GSTM1/GSTT1*-null genotype, and *GSTP1* A/G gene polymorphism and RCC risk for the overall population.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

Retrieval of relevant published articles were conducted in the electronic databases of Cochrane Library, PubMed, and Embase from establishment time of databases to July 1, 2017, and eligible investigations were recruited for our meta-analysis. Key subjects for retrieval consisted of ("glutathione S-transferases" OR "*GSTs*" OR "*GSTM1*" OR "*GSTT1*" OR "*GSTP1*") and ("renal cell carcinoma" OR "renal cancer" OR "RCC"). Additional reports were also recruited through references which were cited in the included investigations, and references of retrieved articles from previous meta-analyses were also inspected.

Inclusion criteria and exclusion criteria {#Sec4}
-----------------------------------------

### Inclusion criteria {#Sec5}

\(1\) prospective study, case-control study, and cross-sectional study; (2) there should be two comparison groups (RCC vs. control); (3) the endpoint had to be RCC; (4) the study should provide detailed data for the genotype distribution.

### Exclusion criteria {#Sec6}

\(1\) primary results were not on *GSTM1*, *GSTT1*, *GSTP1* or outcome; (2) review articles, case reports and editorials; (3) investigated the effect of GST gene expression on disease.

Quality appraisal {#Sec7}
-----------------

In order to evaluate the quality of the recruited investigations that met the inclusive criteria mentioned above, a quality score criteria based on seven aspects of a genetic association investigations was used (Additional file [1](#MOESM1){ref-type="media"}: Table S1). The quality score form was instituted by Thakkinstian et al. in 2005 \[[@CR29]\]. Its range of this form spanned from zero (the worst quality) to 12 (the best quality). Investigations were categorized to be "high quality" when the quality score was more than seven; otherwise, studies were regarded as "low quality". Quality appraisal was implemented by two researchers who were independently responsible for the literature retrieval, and discussions were held until every aspect was entirely consistent by comparison.

Data extraction and data synthesis {#Sec8}
----------------------------------

The following information from each eligible study was excerpted by two investigators independently: the surname of first author, publication year and the sample size of RCC cases and controls for *GSTM1*, *GSTT1*, and *GSTP1* genotypes. Frequencies of genotypes for *GSTM1*, *GSTT1* and *GSTP1* were calculated for each case group and control group. The results were compared, and discussion was performed when there was disagreement. Consistency of data extracted by the two researchers was tested and any disagreement was resolved through discussion.

Statistical analysis {#Sec9}
--------------------

All statistical analyses were performed using Cochrane Review Manager Version 5.3 (Cochrane Library, UK). Fixed-effect model (Mantel-Haenszel method) was used to estimate the pooled statistic. The heterogeneity among the included studies was detected using *I*^*2*^. On the other hand, when the *P-*value from the heterogeneity test was less than 0.1, a random effects model (DerSimonian-Laird method) was conducted. Odds ratios (OR) were used for results of dichotomous data, and 95% confidence intervals (CI) were also counted. A *P* \< 0.05 was regarded as statistical significance for the pooled OR. Publication bias was graphically judged from the Begg adjusted rank correlation test \[[@CR30]\] and the Egger regression asymmetry test \[[@CR31]\], when the number of the included studies was more than six.

Results {#Sec10}
=======

Study characteristics {#Sec11}
---------------------

Fifteen investigations \[[@CR32]--[@CR46]\] were recruited into our meta-analysis to assess the association between the *GSTM1*-null genotype and the susceptibility of RCC (Fig. [1](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). Data was extracted by the sequences of the surname of first author, publication year and the sample size of RCC cases and controls for the *GSTM1* genotype (Table [1](#Tab1){ref-type="table"}). The 15 included reports contained 3782 cases and 5223 controls. The average *GSTM1*-null genotype distribution frequency in controls was 49.83%, and the average genotype distribution frequency of the *GSTM1-*null genotype in patients with RCC was 48.63%, indicating the average *GSTM1*-null genotype distribution frequency in RCC patients was similar to that in the control group (control/RCC = 1.02), suggesting that the *GSTM1*-null genotype was unrelated to RCC.Fig. 1Flow chart of the study search and selectionTable 1Characteristics of studies evaluating the effects of GSTM1 and GSTT1 null genotypes on RCC riskGeneAuthor, YearCountryEthnicitySource of controlsQualityCaseControlLocusScore--+Total--+TotalGSTM1Bruning 1997GermanyCaucasianPopulation-based6182745311748Longuemaux 1999FranceCaucasianHospital-based8898417311794211Sweeney 2000USAMixPopulation-based96363126255250505Buzio 2003ItalyCaucasianHospital-based8505010010892200Moore 2007EuropeCaucasianHospital-based94244879115556771232Wiesenhütter 2007GermanyCaucasianHospital-based8514798167157324Karami 2008EuropeCaucasianHospital-based9303321624433454887Coric 2010SerbiaCaucasianHospital-based84630768696182De Martino 2010AustriaCaucasianHospital-based880671475953112Ahmad 2012IndiaAsianPopulation-based1110294196116134250Salinas-Sanchez 2012SpainCaucasianHospital-based6577613378115193Jia 2014ChinaAsianPopulation-basedNC222850303060Coric 2016SerbiaCaucasianHospital-based887109196137137274Abid 2016PakistanAsianHospital-based8224378602171248419Coric 2017SerbiaCaucasianHospital-based8169136305163163326GSTT1Bruning 1997GermanyCaucasianPopulation-based634245113748Longuemaux 1999FranceCaucasianHospital-based82514817340171211Sweeney 2000USAMixPopulation-based9369012693412505Buzio 2003ItalyCaucasianHospital-based8118910035165200Moore 2007EuropeCaucasianHospital-based916774491120910231232Wiesenhütter 2007GermanyCaucasianHospital-based819799859265324Karami 2008EuropeCaucasianHospital-based9129499628161752913Coric 2010SerbiaCaucasianHospital-based821557652130182De Martino 2010AustriaCaucasianHospital-based8271201472389112Salinas-Sanchez 2012SpainCaucasianHospital-based62211013225138163Ahmad 2012IndiaAsianPopulation-based1112571196106144250Jia 2014ChinaAsianPopulation-basedNC301848253560Coric 2016SerbiaCaucasianHospital-based84415219671203274Abid 2016PakistanAsianHospital-based87248255449330379Coric 2017SerbiaCaucasianHospital-based87922630589237326GSTM1-GSTT1Bruning 1997GermanyCaucasianPopulation-based61444564248Sweeney 2000USAMixPopulation-based91710912649456505Moore 2007EuropeCaucasianHospital-based9828299119911331232Karami 2008EuropeCaucasianHospital-based9363260623508372880Salinas-Sanchez 2012SpainCaucasianHospital-based671261338185193Ahmad 2012IndiaAsianPopulation-based117112519654196250Jia 2014ChinaAsianPopulation-basedNC143448105060Coric 2016SerbiaCaucasianHospital-based8242044363571Abid 2016PakistanAsianHospital-based82952455317333350*NC* not clear

Fifteen studies \[[@CR32]--[@CR46]\] were recruited into our meta-analysis to detect the association of the *GSTT1*-null genotype with RCC susceptibility (Fig. [1](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). Those 15 investigations contained 3735 cases and 5179 controls. The average *GSTT1*-null genotype distribution frequency in controls was 23.02%and the average *GSTT1*-null genotype distribution frequency in RCC cases was 24.62%. Therefore, the average distribution frequency of the *GSTT1*-null genotype in control group was similar to that in cases (control/RCC = 0.94), suggesting that the *GSTT1*-null genotype was also unrelated to RCC.

Nine studies \[[@CR32], [@CR34], [@CR36], [@CR38], [@CR41]--[@CR45]\] were recruited into our meta-analysis to assess the relationship of the dual-null genotype, of individuals lacking both *GSTM1* and *GSTT1*, and the susceptibility of RCC (Fig. [1](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). The nine investigations contained 2679 cases and 3589 controls. The average *GSTM1--GSTT1* dual-null genotype distribution frequency in cases with RCC was 23.71% compared to the average frequency of 20.66% in the controls. The average dual-null genotype of *GSTM1--GSTT1* distribution frequency in RCC patients was slightly increased when compared with that in control group (RCC/control = 1.15).

Eight studies \[[@CR33], [@CR34], [@CR36], [@CR37], [@CR41], [@CR44], [@CR46], [@CR47]\] were included in our study to detect the association of the null genotype of *GSTP1* with the susceptibility of RCC (Fig. [1](#Fig1){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}). These 8 investigations contained 2197 cases and 3323 controls. The average A allele distribution frequency in controls was 70.44%, and the average A allele distribution frequency in RCC cases was 69.11%. The average A allele distribution frequency of *GSTP1* in control group was similar when compared with that in the RCC group (control/RCC = 1.02), suggesting a lack of association of the *GSTP1* A allele with RCC.Table 2Characteristics of studies evaluating the effects of GSTP1 gene polymorphism on RCC riskAuthor, YearCountryEthnicitySource of controlsQuality ScoreCaseControlAAAGGGTotalAAAGGGTotalLonguemaux 1999FranceCaucasianHospital-based8716722160937521189Sweeney 2000USAMixPopulation-based958561613021321662491Wiesenhütter 2007GermanyCaucasianHospital-based8494379913414447325Moore 2007EuropeCaucasianHospital-based9425390959105775481071232Wang 2011ChinaAsianHospital-based9143559207173549236Ahmad 2012IndiaAsianPopulation-based1171992619612610321250Coric 2016SerbiaCaucasianHospital-based844----194115----274Coric 2017SerbiaCaucasianHospital-based874----301141----326

Four studies \[[@CR34], [@CR40], [@CR41], [@CR45]\] were included in our meta-analysis to detect the relationship of *GSTM1* with clinical TNM stage of RCC (Fig. [1](#Fig1){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). Those four investigations contained 501 cases and 423 controls. The average *GSTM1*-null genotype distribution frequency in stage I + II was 47.33%, and the average *GSTM1*-null genotype distribution frequency in stage III + IV was 55.76%. The average *GSTM1*-null genotype distribution frequency in stage I + II was slightly reduced than that in stage III + IV (I + II/III + IV = 0.85).Table 3Characteristics of studies evaluating the effects of GSTM1 and GSTT1 null genotypes on clinical TNM stages of RCCGeneAuthor, YearCountryEthnicitySource of controlsQualityStage I + IIStage III + IVLocusScore--+Total--+TotalGSTM1-TNMSweeney 2000USAMixPopulation-based9505510515823De Martino 2010AustriaCaucasianHospital-based8452974353873Ahmad 2012IndiaAsianPopulation-based115377130491766Abid 2016PakistanAsianHospital-based87711519293168261GSTT1-TNMSweeney 2000USAMixPopulation-based9297610561723De Martino 2010AustriaCaucasianHospital-based8126274155873Ahmad 2012IndiaAsianPopulation-based117258130531366Salinas-Sanchez 2012SpainCaucasianHospital-based6394079251136Abid 2016PakistanAsianHospital-based82116118236200236

Five studies \[[@CR34], [@CR40]--[@CR42], [@CR45]\] were recruited into this meta-analysis to assess the association between *GSTT1* and clinical TNM stages of RCC (Fig. [1](#Fig1){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). Those five studies contained 570 cases and 434 controls. The average *GSTT1*-null genotype distribution frequency in stage I + II was 37.15%, compared to the average frequency of 49.1% in stage III + IV patients. The average *GSTT1*-null genotype distribution frequency in stage I + II was notably reduced than the average *GSTT1*-null genotype distribution frequency in stage III + IV (I + II/III + IV = 0.76).

### Relationship between the *GSTM1*-null genotype and the susceptibility of RCC {#Sec12}

The *GSTM1*-null genotype was found to be not associated with RCC susceptibility in the collective populations, Asians and Caucasians, hospital-based controls, or population-based controls (collective populations: OR = 1.00, 95% CI: 0.92--1.09, *P* = 0.91; Caucasians: OR = 1.02, 95% CI: 0.92--1.12, *P* = 0.72; Asians: OR = 0.95, 95% CI: 0.78--1.17, *P* = 0.65; hospital-based controls: OR = 1.01, 95% CI: 0.92--1.11, *P* = 0.85; population-based controls: OR = 0.87, 95% CI: 0.57--1.33, *P* = 0.52; Fig. [2](#Fig2){ref-type="fig"} for the overall population; Table [4](#Tab4){ref-type="table"}). When only the high-quality investigations were recruited for meta-analysis, this association was also not found (OR = 1.02, 95% CI: 0.93--1.11, *P* = 0.72; Table [4](#Tab4){ref-type="table"}).Fig. 2Association between GSTM1 null genotype and RCC susceptibility in the overall population. CI: confidence intervalTable 4Meta-analysis of the association of GSTM1- and GSTT1-null genotypes and GSTP1 with RCC risk and the relationship between GSTM1, GSTT1 and clinical TNM stages of RCCGenetic contrastsGroup and subgroupsStudies NumberQ test *P*-valueModel selectedOR (95%CI)PGSTM1 - vs +Overall150.23Fixed1.00 (0.92,1.09)0.91Caucasian110.16Fixed1.02 (0.92,1.12)0.72Asian30.23Fixed0.95 (0.78,1.17)0.65Hospital-based110.43Fixed1.01 (0.92,1.11)0.85Population-based40.06Random0.87 (0.57,1.33)0.52High quality120.42Fixed1.02 (0.93,1.11)0.72GSTT1 - vs +Overall150.0006Random1.09 (0.90,1.33)0.38Caucasian110.30Fixed1.00 (0.88,1.13)0.97Asian30.005Random1.73 (0.91,3.28)0.09Hospital-based110.68Fixed1.01 (0.90,1.14)0.84Population-based40.01Random1.62 (0.90,2.91)0.11High quality120.002Random1.09 (0.90,1.32)0.39Dual-null genotype for GSTM1/GSTT1 - vs +Overall90.08Random1.26 (1.00,1.59)0.05Caucasian50.48Fixed1.05 (0.89,1.23)0.58Asian30.22Fixed1.72 (1.24,2.38)0.001Hospital-based50.97Fixed1.07 (0.91,1.25)0.43Population-based40.12Fixed1.70 (1.25,2.32)0.0007High quality60.10Fixed1.17 (1.01,1.36)0.03GSTP1 A vs GOverall60.02Random0.93 (0.77,1.11)0.41Caucasian30.06Random1.02 (0.80,1.31)0.85Asian20.27Fixed0.72 (0.58,0.90)0.003Hospital-based40.10Fixed0.97 (0.87,1.08)0.59Population-based20.02Random0.82 (0.52,1.29)0.39High quality60.02Random0.93 (0.77,1.11)0.41 AA vs AG + GGOverall8\<0.00001Random0.74 (0.55,1.00)0.05Caucasian5\<0.00001Random0.72 (0.46,1.13)0.15Asian20.19Fixed0.66 (0.50,0.88)0.004Hospital-based6\<0.00001Random0.74 (0.51,1.07)0.11Population-based20.02Random0.77 (0.41,1.42)0.40High quality8\<0.00001Random0.74 (0.55,1.00)0.05 GG vs AG + AAOverall60.22Fixed1.14 (0.93,1.40)0.22Caucasian30.07Random0.98 (0.58,1.66)0.95Asian20.51Fixed1.49 (0.90,2.49)0.12Hospital-based40.16Fixed1.10 (0.87,1.40)0.43Population-based20.21Fixed1.26 (0.83,1.91)0.28High quality60.22Fixed1.14 (0.93,1.40)0.22GSTM1-TNM - vs +Overall4\<0.0001Random0.72 (0.30,1.70)0.45Caucasian1--Fixed1.68 (0.88,3.24)0.12Asian2\<0.0001Random0.55 (0.11,2.70)0.46Hospital-based20.39Fixed1.32 (0.95,1.83)0.10Population-based20.23Fixed0.30 (0.18,0.51)\<0.0001High quality4\<0.0001Random0.72 (0.30,1.70)0.45GSTT1-TNM - vs +Overall50.19Fixed0.56 (0.41,0.78)0.0006Caucasian20.36Fixed0.56 (0.31,1.01)0.06Asian20.06Random0.48 (0.21,1.12)0.09Hospital-based30.55Fixed0.64 (0.42,0.97)0.03Population-based20.05Random0.54 (0.16,1.87)0.33High quality40.13Fixed0.59 (0.41,0.85)0.004

### Relationship between the *GSTT1*-null genotype and the susceptibility of RCC {#Sec13}

Association of *GSTT1* null genotype with RCC risk was not found in the overall population, Caucasians and Asians, hospital-based controls, population-based controls (overall population: OR = 1.09, 95% CI: 0.90--1.33, *P* = 0.38; Caucasians: OR = 1.00, 95% CI: 0.88--1.13, *P* = 0.97; Asians: OR = 1.73, 95% CI: 0.95--3.28, *P* = 0.09; hospital-based controls: OR = 1.01, 95% CI: 0.90--1.14, *P* = 0.84; population-based controls: OR = 1.62, 95% CI: 0.90--2.91, *P* = 0.11; Fig. [3](#Fig3){ref-type="fig"} for the overall population; Table [4](#Tab4){ref-type="table"}). When only the high-quality investigations were included for meta-analysis, an association was also not found (OR = 1.09, 95% CI: 0.90--1.32, *P* = 0.39; Table [4](#Tab4){ref-type="table"}).Fig. 3Association between the GSTT1-null genotype and RCC susceptibility in the overall population. CI: confidence interval

### Association of the dual *GSTM1--GSTT1*-null genotype with the susceptibility of RCC {#Sec14}

There was no an association between the dual-null genotype of individuals lacking both *GSTM1*-- and *GSTT1* and RCC risk in the overall population, Caucasians, or hospital-based controls (overall population: OR = 1.26, 95% CI: 1.00--1.59, *P* = 0.05; Caucasians: OR = 1.05, 95% CI: 0.89--1.23, *P* = 0.58; hospital-based controls: OR = 1.07, 95% CI: 0.91--1.25, *P* = 0.43; Fig. [4](#Fig4){ref-type="fig"} for the overall population; Table [4](#Tab4){ref-type="table"}). When only the high-quality studies were recruited for meta-analysis, this association was also not found (OR = 1.17, 95% CI: 1.01--1.36, *P* = 0.03; Table [4](#Tab4){ref-type="table"}). However, stratification into Caucasians and Asians revealed that the dual *GSTM1-GSTT1*-null genotype was associated with the onset of RCC in Asians, when compared to population-based controls (Asians: OR = 1.72, 95% CI: 1.24--2.38, *P* = 0.001; population-based controls: OR = 1.70, 95% CI: 1.25--2.32, *P* = 0.0007; Table [4](#Tab4){ref-type="table"}).Fig. 4Association between dual-null genotype of GSTM1--GSTT1 with RCC risk in the overall population. CI: confidence interval

### Association between the *GSTP1* a/G gene polymorphism and RCC susceptibility {#Sec15}

The *GSTP1* A/G gene polymorphism was not associated with RCC risk in the overall population, Asians and Caucasians, hospital-based controls, or population-based controls (overall population: A allele: OR = 0.93, 95% CI: 0.77--1.11, *P* = 0.41; AA genotype: OR = 0.74, 95% CI: 0.55--1.00, *P* = 0.05; GG genotype: OR = 1.14, 95% CI: 0.93--1.14, *P* = 0.22; Table [4](#Tab4){ref-type="table"}). When only the high-quality studies were recruited for the meta-analysis, this relationship was also not found (A allele: OR = 0.93, 95% CI: 0.77--1.11, *P* = 0.41; AA genotype: OR = 0.74, 95% CI: 0.55--1.00, *P* = 0.05; GG genotype: OR = 1.14, 95% CI: 0.93--1.14, *P* = 0.22; Table [4](#Tab4){ref-type="table"}).

### Relationship between the *GSTM1*-null genotype and clinical TNM stages of RCC {#Sec16}

*GSTM1*-null genotype was not associated with the clinical TNM stages of RCC in the overall population, Caucasians, Asians, or hospital-based controls (overall population: OR = 0.72, 95% CI: 0.30--1.70, *P* = 0.45; Caucasians: OR = 1.68, 95% CI: 0.88--3.24, *P* = 0.12; Asians: OR = 0.55, 95% CI: 0.11--2.70, *P* = 0.46; hospital-based controls: OR = 1.32, 95% CI: 0.95--1.83, *P* = 0.10; Table [4](#Tab4){ref-type="table"}). When only the high-quality studies were recruited for meta-analysis, this association was also not found (OR = 0.72, 95% CI: 0.30--1.70, *P* = 0.45; Table [4](#Tab4){ref-type="table"}). Interestingly, the *GSTM1*-null genotype was associated with the clinical TNM stages of RCC when the meta-analysis was compared to population-based controls (OR = 0.30, 95% CI: 0.18--0.51, *P*\<0.0001; Table [4](#Tab4){ref-type="table"}).

### Association of the *GSTT1*-null genotype with clinical TNM stages in patients with RCC {#Sec17}

The *GSTT1*-null genotype was not associated with clinical TNM stage of RCC in Caucasians or Asians vs. population-based controls (Caucasians: OR = 0.56, 95% CI: 0.31--1.01, *P* = 0.06; Asians: OR = 0.48, 95% CI: 0.21--1.12, *P* = 0.09; population-based controls: OR = 0.54, 95% CI: 0.16--1.87, *P* = 0.33; Table [4](#Tab4){ref-type="table"}). When only high-quality studies were included for the meta-analysis, association of the *GSTT1*-null genotype with clinical TNM stage of RCC was found (OR = 0.59, 95% CI: 0.41--0.85, *P* = 0.004; Table [4](#Tab4){ref-type="table"}). Interestingly, the *GSTT1*-null genotype was found to be associated with the clinical TNM stages in patients with RCC in the overall population, and when the meta-analysis included hospital-based controls (overall populations: OR = 0.56, 95% CI: 0.41--0.78, *P* = 0.0006; hospital-based controls: OR = 0.64, 95% CI: 0.42--0.97, *P* = 0.03; Table [4](#Tab4){ref-type="table"}).

Evaluation of publication bias {#Sec18}
------------------------------

A publication bias test was performed for the association of the *GSTM1*-null genotype, *GSTT1*-null genotype, *GSTM1*-null/*GSTT1*-null genotype, and *GSTP1* A/G gene polymorphism with RCC risk, when compared to the overall population. No publication biases for the relationship between the *GSTM1*-null genotype or *GSTT1*-null genotype and RCC risk was determined in the overall population (*GSTM1*: Begg *P* = 0.692, Egger *P* = 0.400; *GSTT1*: Begg *P* = 0.166, Egger *P* = 0.095; *GSTM1*-null/*GSTT1*-null genotype: Begg *P* = 0.917, Egger *P* = 0.628; *GSTP1* A/G gene polymorphism: Begg *P* = 0.902, Egger *P* = 0.290; Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Publication bias A: GSTM1-null genotype; B: GSTT1-null genotype; C: dual null genotype for GSTM1/GSTT1; D: GSTP1 A/G gene polymorphism. Each point represents a separate study for the indicated association. Log or represents natural logarithm of OR. Vertical line represents the mean effects size

Discussion {#Sec19}
==========

In this study, we found that the average *GSTM1*-null genotype distribution frequency in patients with RCC is similar with the average *GSTM1*-null genotype distribution frequency in the control group, indicating that the *GSTM1-*null genotype is not associated with RCC susceptibility. We performed the meta-analysis in further depth, and still found that there is no an association between null genotype for *GSTM1* and RCC risk in the overall population of Caucasians and Asians, hospital-based controls, population-based controls, high-quality studies. Publication bias was also tested and not found for *GSTM1*. Our results indicate that the *GSTM1*-null genotype does not predict the susceptibility of RCC. The sample size in our meta-analysis was larger than other meta-analyses \[[@CR43], [@CR48]--[@CR51]\].

The average *GSTT1*-null genotype distribution frequency in patients with RCC was also similar to the average *GSTT1*-null genotype distribution frequency in the control group, indicating that the null genotype for *GSTM1* is also not associated with RCC susceptibility. For confirmation, a meta-analysis was performed and showed that there was no an association between null genotype of *GSTM1* and the RCC susceptibility in the overall population, Caucasians and Asians, hospital-based controls, population-based controls. When only the high-quality studies were recruited for meta-analysis, this association was also not found. Publication bias was also tested and not found for *GSTT1*. Our results indicate that the *GSTT1*-null genotype does not predict the RCC susceptibility. The sample size in our meta-analysis was larger than other meta-analyses \[[@CR43], [@CR48]--[@CR50]\].

The average *GSTM1*-null/*GSTT1*-null genotype distribution frequency in patients with RCC is slightly increased. This could indicate that the dual-null genotype, of individuals lacking both *GSTM1* and *GSTT1*, might be associated with the susceptibility of RCC. However, further meta-analysis to detect the risk of the *GSTM1*-null/*GSTT1*-null genotype for RCC susceptibility showed no association between the *GSTM1*-null/*GSTT1*-null genotype and RCC susceptibility in the overall population of Caucasians, compared to hospital-based controls, when only high-quality studies were recruited in the meta-analysis. However, the dual-null genotype was associated with the onset of RCC in Asians, when compared to population-based controls. There was no publication bias for this meta-analysis. As above, the sample size in our meta-analysis was larger than other meta-analyses \[[@CR48], [@CR50]\].

The association of the *GSTP1* A/G gene polymorphism with the susceptibility of RCC was also characterized. The average A allele distribution frequency of *GSTP1* in patients with RCC was similar when compared with that in control group, suggesting that there was no association of the *GSTP1* A/G gene polymorphism with RCC susceptibility. We also conducted a meta-analysis and confirmed that the *GSTP1* A/G gene polymorphism is not associated with RCC risk in the overall population of Caucasians and Asians examined, and regardless of whether controls were hospital-based or population-based, and whether high quality studies were solely used. No publication bias was found in this meta-analysis. Furthermore, the sample size in this meta-analysis was notable larger than other meta-analyses \[[@CR43], [@CR49]\].

We have also assessed the relationship between *GSTM1* and clinical TNM stages in patients with RCC. The average *GSTM1*-null genotype distribution frequency in stage I + II is slightly lower when compared with that in stage III + IV RCC (I + II/III + IV = 0.85). This might indicate that the *GSTM1*-null genotype is associated with RCC TNM stage. However, meta-analysis of the high-quality studies indicates no association of *GSTM1*-null genotype with clinical TNM stages of RCC is present in the overall population of Caucasians and Asians, compared to hospital-based controls. Interestingly, the *GSTM1*-null genotype is associated with the clinical TNM stages of RCC when the meta-analysis included controls from the population. The sample size of our meta-analysis is notable larger than other meta-analyses \[[@CR29]\]. However, more studies are required for confirmation.

The relationship between *GSTT1* and clinical TNM stages of RCC is also assessed. The average *GSTT1*-null genotype distribution frequency in stage I + II is notably lower when compared with that in stage III + IV RCC (I + II/III + IV = 0.76). This might indicate a lack of association of the *GSTT1*-null genotype with clinical TNM stages of RCC in Caucasians and Asians, when compared to population-based controls (Table [4](#Tab4){ref-type="table"}). When only the high-quality studies were included for meta-analysis, this association was also found (Table [4](#Tab4){ref-type="table"}). Interestingly, the *GSTT1*-null genotype is found to be associated with the clinical TNM stages in patients with RCC in the overall population when the meta-analysis includes hospital-based controls. The *GSTT1*-null genotype is also found to be associated with the clinical TNM stages in patients with RCC in the overall population, when compared to hospital-based controls, and in the meta-analysis including high quality studies. Again, the sample size of our meta-analysis is larger than a previous meta-analysis \[[@CR49]\]. However, more studies should be performed.

Cheng et al. \[[@CR50]\] conducted a meta-analysis that included six investigations for *GSTM1*, six reports for *GSTT1*, and four studies for the dual-null genotype for *GSTM1* and *GSTT1*, and reported that no association was found between the *GSTM1*-null/*GSTT1*-null genotype and RCC susceptibility. The authors also performed a *GSTM1-GSTT1* interaction analysis and indicated that the dual *GSTM1/GSTT1*-null genotype was not significantly associated with the susceptibility of RCC. Liu et al. \[[@CR51]\] performed a meta-analysis on eight studies and showed that the *GSTM1*-null genotype was not significantly associated with susceptibility of RCC. Yang et al. \[[@CR49]\] conducted a meta-analysis recruited 10 studies of *GSTM1*, 10 reports of *GSTT1*, and five studies of *GSTP1*, and reported that *GSTM1*, *GSTT1* and *GSTP1* gene polymorphisms were not associated with the development of the RCC disease. Jia et al. \[[@CR43]\] performed a meta-analysis on 10 studies of *GSTM1*, 10 reports of *GSTT1*, five studies of dual *GSTM1-GSTT1*-null genotype, six studies of *GSTP1*, and concluded that *GSTM1*, *GSTT1*, and *GSTP1* gene polymorphisms were not to be associated with the risk of RCC. Also, *GSTM1-GSTT1* interaction analysis indicated that the dual null genotype for *GSTM1/GSTT1* was notably associated with an increased RCC susceptibility. Huang et al. \[[@CR48]\] analyzed eight studies of *GSTM1*, eight studies of *GSTT1*, three studies of *GSTM1* gene polymorphism and clinical TNM stages, and four studies on *GSTM1* and *GSTT1* gene polymorphism and clinical TNM stages, and indicated that *GSTM1* and *GSTT1* gene polymorphisms were not markedly associated with RCC susceptibility in a recessive model. However, comparison of the wild-type genotype versus the dual *GSTM1-GSTT1*-null genotype showed a positive association with the susceptibility of RCC. The authors also identified an association of wild-type *GSTT1* with low RCC TNM stages. A strong association between *GST* genotypes and polymorphism and risk of renal cancer is not there in the total population. The conclusion of all these studies is that *GST* genotypes and polymorphisms cannot be used as biomarkers for early diagnosis.

In this meta-analysis, there are some limitations. First, there was heterogeneity among the recruited studies for the reason that the patients and controls were from different races, and the controls were population-based or hospital-based. Second, geographic origin might affect the relationship between *GSTs* gene polymorphism and RCC susceptibility, and we did not conduct a sub-group analysis. Furthermore, the quality of the recruited articles was different. These factors might prevent us from drawing a more robust conclusion. In addition, although our sample size is larger than prior meta-analyses, but more original studies continue to be needed to draw a more robust conclusion. More well-designed investigations should be conducted in the future.

Conclusion {#Sec20}
==========

The results in this study support that there is an association of the dual *GSTM1-GSTT1*-null genotype with RCC susceptibility in Asians, and there is an association between the *GSTT1*-null genotype and clinical TNM stage of RCC in the overall population. However, more association studies are required to be conducted to further clarify these relationships.
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GSH

:   Glutathione

GST

:   Glutathione S-transferase

RCC

:   Renal cell carcinoma

TNM

:   Tumor node metastasis
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